UBS analyst Timothy Arcuri maintains Applied Materials (NASDAQ:AMAT) with a Neutral and raises the price target from $90 to $98.
Vaxcyte Reports Expansion Of Its CARB-X Award To Advance Development Of VAX-A1 To Prevent Group A Streptococcus Infections; Award Commits Added $3.2M In Funding, Total Potential Funding $29.7M Based On Milestones
-- Award Commits an Additional $3.2 Million in Funding; Total Potential Funding of $29.7 Million Based on Future Milestones --
-- Vaxcyte Plans to Initiate IND-Enabling Studies for VAX-A1 in Second
